LENSAR (NASDAQ:LNSR) Issues Quarterly Earnings Results

LENSAR (NASDAQ:LNSR) released its earnings results on Thursday. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.26, Zacks reports. The business had revenue of $16.50 million during the quarter, compared to analyst estimates of $14.65 million. LENSAR had a net margin of 57.57% and a negative return on equity of 253.03%.

Here are the key takeaways from LENSAR’s conference call:

• Q2 revenue increased 18% year over year to $16.5 million, while recurring revenue rose 20% to $13.7 million and procedure revenue grew 23% to $10.2 million.
• LENSAR placed 10 ALLY systems during the quarter, expanding the global installed base to approximately 445 systems, with 13 ALLY systems in backlog; procedure volume increased 13% to 58,682 and U.S. procedure market share reached 24.1%.
• The company reported its strongest adjusted EBITDA performance to date at $3.6 million, supported by revenue growth, a greater mix of recurring revenue, and lower expenses; gross margin was 52% excluding a $1.1 million tariff refund.
• Cash and equivalents declined to $13.6 million from $18 million at year-end 2025, and management expects operating expenses to rise toward historical levels as it increases commercial investment, creating potential variability in EBITDA over the next several quarters.
• Management cautioned that third-quarter cataract procedure volumes are historically lower because of seasonal holidays and vacations, while rebuilding overseas distributor relationships is expected to take several quarters.

LENSAR Price Performance

LENSAR stock opened at $8.20 on Friday. The firm has a 50 day simple moving average of $5.89 and a 200-day simple moving average of $7.37. The stock has a market cap of $100.71 million, a price-to-earnings ratio of -24.85 and a beta of 0.89. LENSAR has a 1-year low of $4.95 and a 1-year high of $12.96.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in LNSR. Geode Capital Management LLC grew its position in LENSAR by 103.9% in the second quarter. Geode Capital Management LLC now owns 219,373 shares of the company’s stock worth $2,890,000 after acquiring an additional 111,802 shares during the period. Rangeley Capital LLC acquired a new stake in shares of LENSAR during the second quarter valued at about $658,000. Dynamic Technology Lab Private Ltd raised its stake in shares of LENSAR by 436.6% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 54,166 shares of the company’s stock valued at $630,000 after acquiring an additional 44,072 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of LENSAR in the 1st quarter valued at approximately $546,000. Finally, Gabelli Funds LLC lifted its holdings in shares of LENSAR by 277.8% in the 2nd quarter. Gabelli Funds LLC now owns 51,000 shares of the company’s stock worth $672,000 after acquiring an additional 37,500 shares during the last quarter. 40.15% of the stock is currently owned by institutional investors and hedge funds.

LENSAR News Roundup

Here are the key news stories impacting LENSAR this week:

• Positive Sentiment: LENSAR reported second-quarter revenue of $16.5 million, above analysts’ $14.65 million consensus estimate, and earnings of $0.10 per share versus expectations for a $0.16 loss. The results point to a significant improvement in profitability and operating performance. LENSAR Reports Second Quarter 2026 Results and Provides Business Update
• Positive Sentiment: The company placed 10 ALLY Robotic Cataract Laser Systems during the quarter, increasing its installed base to 445 systems. The ALLY backlog stood at 13 systems at June 30, suggesting continued near-term demand and potential future revenue. LENSAR signals opex to rise modestly as ALLY backlog reaches 13 systems
• Positive Sentiment: Recurring revenue reached $13.7 million, while ALLY placements grew 30%. The recurring-revenue base could improve visibility and support more consistent results as the installed system base expands. LENSAR Q2 2026 Earnings Call Highlights
• Positive Sentiment: BTIG Research raised its LENSAR price target from $7 to $9 and assigned a Buy rating, reflecting greater confidence following the earnings beat and business update.
• Neutral Sentiment: Management indicated that operating expenses will increase modestly, likely reflecting investments needed to support commercialization and the growing ALLY system base. This could temper the pace of future margin expansion.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LNSR. Lake Street Capital reissued a “buy” rating and issued a $13.00 price target on shares of LENSAR in a research note on Thursday. BTIG Research upped their price target on LENSAR from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday. Wall Street Zen raised LENSAR from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of LENSAR in a research report on Friday, August 7th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $11.00.

About LENSAR

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.